Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is expected to see growth and profitability in the future, driven by their multi-year plan with three acts. The first act has focused on driving growth in the US market and the second act includes the launch of a new product, with strong demand and positive early feedback. The company remains conservative in their projections but has a goal to convert their US install base to the pharmacy channel for long-term revenue and profit growth, with potential risks and uncertainties to consider such as competition and challenges with new product launches.

Bears say

Tandem Diabetes Care is expected to face challenges in both growth and profitability in the coming years, as competition enters the automated insulin delivery market and the majority of the company's installed base converts to insurance coverage. Additionally, the company's reliance on the US market and disposable infusion sets may limit its potential for international expansion and diversification. With a valuation already factoring in future success, it remains to be seen if Tandem Diabetes Care can deliver sustained top-line growth and justify a higher valuation.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.